Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina

European Heart Journal

Volumn 20, Issue 15, 1999, Pages 1101-1111

  Klootwijk, P ^a   Lenderink, T ^b   Meij, S ^a   Boersma, H ^a   Melkert, R ^b   Umans, V A W ^c   Stibbe, J ^a   Muller E J ^d   Poortermans, K J ^e   Deckers, J W ^a   Simoons, M L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARDIALYSIS   (Netherlands)

^c Northwest Clinics   (Netherlands)

^d N   (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Anti thrombin; ECG ischaemia monitoring; Efegatran; Unstable angina

Indexed keywords

ANTICOAGULANT AGENT; EFEGATRAN; HEPARIN; THROMBIN; THROMBIN INHIBITOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; DEVICE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; THROMBIN TIME; THROMBOPHLEBITIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANGINA, UNSTABLE; ANTICOAGULANTS; ANTITHROMBINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; OLIGOPEPTIDES; PARTIAL THROMBOPLASTIN TIME; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0033179314     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1477     Document Type: Article

References (21)

1. Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
2. Rehr R, Disciascio G, Vertovec G, Crowley M. Angiographic morphology of coronary artery stenoses in prolonged rest angina: Evidence of intracoronary thrombosis. J Am Coll Cardiol 1989; 14: 1429-37.
3. Gorlin R, Fuster V, Ambrose JA. Anatomic-physiologic links between acute coronary syndromes. Circulation 1986; 74: 6-9.
4. Coller BS. Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol 1986; 103: 451-6.
5. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T. Fibrinogen-independent platelet adhesion, and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 1989; 83: 288-97.
6. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-84.
7. Klootwijk P, Meij S, Melkert R, Lenderink T, Simoons ML. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation 1998; 98: 1358-64.
8. Klootwijk P, Krucoff MW, Akkerhuis M, et al. Recurrent ischemia in patients with unstable angina or myocardial infarction without ST-elevation treated with eptifibatide predicts mortality and (re)infarction. A report from the PURSUIT study. Eur Heart J 1998; 19 (Abstract Suppl): 3419.
9. Klootwijk P, Meij S, v. Es GA, et al. Comparison of usefulness of computer assisted continuous 48-hours 3-lead with 12-lead ECG ischaemia monitoring for detection and quantitation of ischaemia in patients with unstable angina. Eur Heart J 1997; 18: 931-40.
10. Zoldhelyi P, Webster MW, Fuster V, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993; 88: 2015-22.
11. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21.
12. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 12: 335: 775-82.
13. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) trial investigators. Circulation 1997; 96: 2155-61.
14. Bittl JA, Adelman B, Deutsch E et al. for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-9.
15. Neuhaus KL, von Essen R, Tebbe U et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 1994; 90: 1638-42.
16. Antman EM for the TIMI 9A investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
17. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study. Circulation 1997; 96: 769-77.
18. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
19. Serruys PW, Herrman JP, Simon R et al. for the Helvetica Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica investigators. N Engl J Med 1995; 333: 757-63.
20. Simoons MI. Prevention and management of thrombotic complications during coronary interventions. Foreword. Eur Heart J 1995; 16 (Suppl L): 1-2.
21. Zoldhelyi P, Janssens S, Lefevre G, Collen D, Van de Werf F, for the GUSTO-IIA Investigators. Effects of heparin and hirudin (CGP39393) on thrombin generation during thrombolysis for acute myocardial infarction. Circulation 1995; 92: 1-740.